Adaptation of an in vitro one-compartment pharmacodynamic chemostat for testing efficacy of ceftazidime against Burkholderia pseudomallei outside a BSL3 facility

Adaptation of an in vitro one-compartment pharmacodynamic chemostat for testing efficacy of ceftazidime against Burkholderia pseudomallei outside a BSL3 facility

Non-clinical pharmacokinetic-pharmacodynamic (PKPD) models are crucial in the initial design of drug-dosage regimens and in drug development but has rarely been employed for testing high-risk organisms due to stringent handling procedures. Burkholderia pseudomallei is classified as a Tier 1 select a...

Full description

Saved in:
Bibliographic Details
Main Authors: Hana Farizah Zamri, Mohammad Ridhuan Mohd Ali, Ahmad Izzan Irfan Sha'ari, Nurul Husna Mohd Mazalan, Norazah Ahmad, Nur Asyura Nor Amdan, Nusaibah Abdul Rahim, Zakuan Zainy Deris
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:MethodsX
Subjects:
In vitro one-compartment chemostat for evaluating ceftazidime PK/PD against B. pseudomallei
Online Access:http://www.sciencedirect.com/science/article/pii/S2215016125000159
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-clinical pharmacokinetic-pharmacodynamic (PKPD) models are crucial in the initial design of drug-dosage regimens and in drug development but has rarely been employed for testing high-risk organisms due to stringent handling procedures. Burkholderia pseudomallei is classified as a Tier 1 select agent with international guidelines recommending this organism to be handled within a biosafety level 3 (BSL3) facility. Unfortunately, BSL3 facilities are not widely available in low-resource settings. This paper describes a detailed guide for setting up an in vitro pharmacodynamic infection model specific for testing B. pseudomallei outside BSL 3 laboratory. Briefly in this study, • All procedures involving active handling of live B. pseudomallei cultures were performed strictly inside a class II BSC in BSL-2 plus negative airflow laboratory. • The model was set to simulate B. pseudomallei-bacteremia treated with ceftazidime, a 1st-line anti-melioidosis drug with an approximate 2-hour half-life. Model validation was performed by simulating ceftazidime half-life. • For the pharmacodynamic study, ceftazidime was given as bolus injections at 8-hour intervals into the central culture chamber containing actively growing B. pseudomallei.
ISSN:2215-0161

Similar Items